Pasireotide vs Prostatilen
Overview
Pasireotide and Prostatilen are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares Pasireotide and Prostatilen across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Pasireotide | Prostatilen | |
|---|---|---|
| Category | Hormonal | Hormonal |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) | 10 mg |
| Frequency | Twice daily (SC formulation) or every 4 weeks (LAR formulation) | daily for cycles |
| Reported benefits | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism | Prostate health, reproductive function, hormone balance |
| Reported side effects | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) | Well-tolerated |
Key differences
Primary use. Pasireotide is categorised under Hormonal, while Prostatilen falls under Hormonal. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. Pasireotide: FDA-approved. Prostatilen: not FDA-approved; treated as a research compound.
Dosing. Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)). Prostatilen is typically dosed at 10 mg (daily for cycles).
Can you stack them?
Some protocols combine peptides, but stacking Pasireotide and Prostatilen has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Pasireotide and Prostatilen?
- Pasireotide and Prostatilen are both hormonal peptides, but they differ in mechanism, dosing, and regulatory status. Pasireotide is FDA-approved for one or more indications, whereas Prostatilen is not FDA-approved; generally classified as a research compound.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- What is Prostatilen used for?
- Prostate and male hormone support.
- Can you take Pasireotide and Prostatilen together?
- Some users combine peptides within a single protocol, but stacking Pasireotide and Prostatilen has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Pasireotide or Prostatilen FDA-approved?
- Pasireotide is FDA-approved for one or more indications. Prostatilen is not FDA-approved; generally classified as a research compound.
Read the full articles
- Pasireotide — full monograph: mechanism, research, dosing & references
- Prostatilen — full monograph: mechanism, research, dosing & references